Volver a Agenda
Session Chair(s)
Nancy Bradish Myers, JD
CEO and Founder
Catalyst Healthcare Consulting, United States
Learning Objective : Identify lessons learned under FDA’s new Breakthrough Therapy designation; Recognize how to apply these lessons and plan for changes as it evolves in its second year of implementation
Speaker(s)
Patient Advocacy Perspective on Breakthrough Therapy at One Year
Jeff Allen, PHD
Friends of Cancer Research, United States
President and Chief Executive Officer
Industry/Manufacturing Perspective on Breakthrough Therapy at One Year
Earl S. Dye, PHD
Genentech, A Member of the Roche Group, United States
Director, Technical Regulatory Policy
Industry Perpective on Breakthrough Therapy at One Year
Urte Gayko, PHD
Pharmacyclics, United States
Senior Vice President, Global Regulatory Affairs
¿Tiene una cuenta?